Neo-adjuvant intraperitoneal chemotherapy (irinotecan) combined with systemic chemotherapy (mFOLFOX-4 and bevacizumab) prior to cytoreductive surgery and HIPEC for patients with isolated resectable colorectal peritoneal metastases. A phase II, multicentre study.
Erasmus Medical Center (Sponsor)
Adress: Dr. Molewaterplein 40, 3015 GD Rotterdam
Principal investigator: dr. Eva Madsen
Email: e.madsen@erasmusmc.nl
Name researcher: Julie Hamm
Email: j.hamm@erasmusmc.nl
Tel.: 010-704 29 85
Catharina ziekenhuis Eindhoven
Adress: Michelangelolaan 2, 5623 EJ Eindhoven
Local Investigator: Prof. dr. Ignace De Hingh
Email: Ignace.d.hingh@catharinaziekenhuis.nl
Name researcher: Laskarina Galanos
Email: laskarina.galanos@catharinaziekenhuis.nl
Tel.: +31 40 239 52 64
Antoni van Leeuwenhoek (NKI)
Adress: Plesmanlaan 121, 1066 CX Amsterdam
Local Investigator: dr. Niels Kok
Email: n.kok@nki.nl
Name researcher: Lizzel van der Snee
Email: l.vd.snee@nki.nl
Tel.: 020-5122989
Amsterdam Universitair Medisch Centrum (not open for inclusions)
Adress: Meibergdreef 9, 1105 AZ Amsterdam
Local Investigator: Prof. dr. Jurriaan Tuynman
Email: j.tuynman@amsterdamumc.nl
Name researcher: Lars van Kesteren
Email: l.vankesteren1@amsterdamumc.nl
Tel.: 06-40947115
Rationale
For colorectal cancer patients with limited peritoneal metastases (PCI<20), the only curative intent treatment option is to undergo cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). Although CRS-HIPEC offers curation for some, recurrence in the peritoneal cavity is very common. Previous research suggests that patients with peritoneal metastases may benefit from additional intraperitoneal (IP) chemotherapy prior to CRS-HIPEC.
Primary objective
Primary endpoint of this phase 2 trial is the feasibility of IP chemotherapy in addition to systemic chemotherapy prior to CRS-HIPEC in patients with resectable PM of colorectal origin.
Study design
Multicenter, single-arm, phase II trial, including 40 patients.
Study population
Adults with a good performance status (WHO), histological/cytological confirmation of a non-appendiceal colorectal carcinoma with <50% signet ring cells in peritoneal deposits or ascites, resectable disease confirmed by laparotomy or laparoscopy, no systemic metastases, no systemic therapy 6 months in the past 6 months, no resection of systemic metastases in the past 6 months, no contraindications for the planned systemic therapy regimens, and no previous cytoreductive surgery with HIPEC.
Secondary endpoints
Secondary endpoints in this trial are histopathological and radiological treatment response, safety of the treatment, the potential value of PET-CT in treatment response monitoring, quality of life (EQ-5D-5L, QLQ-C30, QLQ-CR29, iMTA productivity cost questionnaire, iMTA medical consumption questionnaire) and disease-free survival, which is assessed until six months after CRS-HIPEC.
All patients in this trial will receive additional intravenous and IP treatment prior to CRS and HIPEC. According to standard of care in the Netherlands, patients undergo a diagnostic laparoscopy to evaluate the PCI-score. In case of a PCI-score between 1-20, a peritoneal access port for IP administration of irinotecan is placed.
Simultaneously with IP irinotecan, patients receive intravenous 5-fluorouracil/leucovorin with oxaliplatin and bevacizumab. Depending on response and tolerability, patients receive a maximum of six cycles, the last two without bevacizumab.
Realisatie door Webfresh